A c c e p t e d M a n u s c r i p t responsible for severe opportunistic infections in humans [1] . Direct inoculation through the skin is possible [2] , but most Nocardia infections occur via the respiratory tract, with possible subsequent dissemination to other tissues, such as brain, skin and subcutaneous tissues [1] . Nocardia can infect immunocompetent patients, but invasive nocardiosis is mainly observed in patients with immune deficiency [3] , including that associated with corticosteroid therapy, transplantation, human immunodeficiency virus (HIV) infection [4, 5] , cancer [6] , chronic granulomatous disease [7] or presence of auto-antibodies against granulocyte-macrophage colony stimulating factor [8] and/or in patients with chronic lung disease [9, 10] .
Solid organ transplant recipients are at risk of opportunistic events, such as Nocardia infections [11] , and nocardiosis has been described in these patients since the early years of solid organ transplantation (SOT) in the 1960s [12] . The risk of developing nocardiosis after SOT varies with the type of organ transplanted, the highest infection rates being observed after lung transplantation (estimates between 0.8% and 3.5%) and the lowest after liver and kidney transplantations (0.04-1.2%) [13] [14] [15] [16] [17] [18] [19] . Nocardia infection after SOT is a severe disease associated with a mortality rate of about 20% [19] . Managing these opportunistic infections is difficult, especially because of the need for long-term treatment (usually 6 to 12 months) to avoid relapses, and the toxicity of the antibiotics, particularly when combined with immunosuppressive drugs [11] .
Despite these therapeutic challenges and poor outcomes, little is known about the risk in the preceding six months. This study provided considerable insight into our understanding of nocardiosis after SOT, but was conducted in a single center with a limited number of cases. To increase the statistical power to detect risk factors, we therefore conducted a retrospective casecontrol study of Nocardia infections in a large number of SOT centers in Western Europe.
Our main objective was to identify risk factors for Nocardia infections in SOT recipients. A secondary aim was to describe the clinical, biological and radiological presentation of nocardiosis in this population.
MATERIAL & METHODS

Study design, setting and participants
This was an international nested case-control study. All Belgian, French and Swiss hospitals with an SOT program were asked to participate in the study and two other European transplantation centers also took part: Leiden University Medical Center (Leiden, The Netherlands) and University Hospital 12
de Octubre (Madrid, Spain). To avoid selection bias, cases were identified in each institution using a systematic and comprehensive screening of local microbiological, pathology and transplantation databases. In France, the study was approved by the CPP Ile-de-France I Ethical board (March 7, 2014) . In other countries, the participating centers obtained approval from their respective Ethics Committees before joining the study.
Inclusion criteria
Patients meeting all the following criteria were included in the study: (1) 
Microbiology
To identify the species of each Nocardia strain, amplification and sequencing of a fragment of the gene coding for the 16S ribosomal RNA (16S rRNA) or hsp65 were mandatory [21] . Briefly, around 500 base pairs of the 16S rRNA gene were sequenced using polymerase chain reaction (PCR), as described previously [22] . Sequences were compared with those stored in GenBank using blast alignment software (http://www.ncbi.nlm.nih.gov/blast) and BIBI (Bio Informatic Bacteria Identification tool; http://pbil.univ-lyon1.fr/bibi) [3] . Identification at the species level required 99% sequence similarity with the type strain of a single species. If required, the hsp65 gene was amplified and sequenced to allow adequate identification [23] . For strains that were not analyzed using molecular methods, species identification was not considered reliable. However, the Nocardia genus could be identified using a validated non-PCR method, such as matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) spectrometry or phenotypic testing showing aerobic filamentous and branching Gram-positive rods, lysozyme-resistant with aerial hypha [1, 24] .
When needed, stored samples were sent a posteriori to the French expert laboratory for nocardiosis (Observatoire Français des Nocardioses, Lyon, France) to perform missing analyses and obtain molecular identification. 
Statistical analysis
RESULTS
Characteristics of the patients
We included a total of 117 cases of nocardiosis from 23 French (n=74), 7 Belgian (n=28), 4 Swiss (n=5), 1 Dutch (n=7) and 1 Spanish (n=3) transplant centers, and 234 matched controls. Only one of these cases has been reported previously [25] . The patients' characteristics are shown in 
Characteristics and outcome of post-transplant nocardiosis
The clinical, biological and radiological characteristics of the nocardiosis cases are shown in Table 2 .
The most frequent clinical presentation was pulmonary disease (101/117, 86.3%) and in 55 (54.5%) of these cases the lung was the only site of infection. Among the patients with lung involvement, a lung computed tomography (CT)-scan was performed for initial workup in 91 cases (90.1%) and nocardiosis had significantly lower lymphocyte counts two months after transplantation and one month before diagnosis than did the control patients.
In the multivariable analysis, high blood calcineurin inhibitor trough levels in the month before diagnosis, use of tacrolimus at the time of diagnosis, corticosteroid dose at the time of diagnosis, patient age and length of stay in the ICU after SOT were significantly associated with the development of nocardiosis ( Table 3) . Nocardiosis did not occur earlier in patients who had a short length of stay in the ICU after SOT (<8 days), when compared with those with a long length of stay (≥8 days): 17 vs. 20 months after transplantation, respectively (p=NS, Kruskal-Wallis test).
Effect of anti-Pneumocystis prophylaxis with cotrimoxazole on the risk of nocardiosis
Twenty-one of the nocardiosis cases (18%) were receiving anti-Pneumocystis prophylaxis with TMP-SMX at the time of diagnosis compared with 57 (24.5%) of the control patients (OR, 0.36; 95% CI, 0.14-0.93; p=0.03). In multivariable analysis, use of TMP-SMX prophylaxis was not found to be protective against occurrence of nocardiosis. The mean weekly dose of SMX was 1819 (±668) mg in cases vs. 2161 (±957) mg in control patients (p=NS). Among the 351 patients, only two of the control patients (0.6%) were receiving high-dose prophylaxis (i.e., 160/800 mg of TMP-SMX daily).
Regarding the 21 episodes of nocardiosis breaking through TMP-SMX prophylaxis, antimicrobial testing was performed on 19 of these cases (90.5%) and 15/19 isolates (78.9%) were susceptible to TMP-SMX.
DISCUSSION
We report the results from the first multicenter case-control study on nocardiosis after SOT. We describe the clinical, biological and radiological presentations of Nocardia infection and identified 5
variables that were significantly associated with the occurrence of this opportunistic event in multivariable analysis: a high blood trough level of calcineurin inhibitor in the month before Although nocardiosis is an opportunistic infection that has been described since the very early years of SOT, there are a number of unsolved issues that still need to be addressed. Indeed, most of the publications on this topic have been case reports or small, uncontrolled series that did not allow evaluation of the risk factors that may lead to post-transplant nocardiosis. However, identifying risk factors in this population is important because Nocardia infection is a rare but lifethreatening event and patients could benefit from prevention, early diagnosis and appropriate treatment. In a case-control study in a single center in Pittsburgh (USA), Peleg and colleagues identified three risk factors for nocardiosis: use of high-dose steroids, a high calcineurin inhibitor level in the month prior to diagnosis and CMV disease in the 6 months prior to diagnosis [15] .
Although our two studies differ in location (USA vs. Europe), study period (1995-2005 vs.
2000-2014) and design (single center vs. multicenter), both indicate that a high degree of immune suppression (i.e., high exposure to calcineurin inhibitors and corticosteroids) plays a key role in the development of nocardiosis in SOT recipients. Furthermore, we showed that use of tacrolimus (a variable that was not recorded by Peleg and coworkers) was independently associated with development of nocardiosis, as has been previously suggested [26, 27] . Interestingly, previous studies have reported a protective role of tacrolimus against the development of opportunistic fungal infections, including Pneumocystis jirovecii pneumonia and mucormycosis [28, 29] . This apparent discrepancy may be explained by a direct anti-fungal effect of tacrolimus or by the inhibition of a specific anti-Nocardia T-cell or macrophage function [30] . Alternatively, tacrolimus use may reflect a greater state of overall immunosuppression as this drug is often used in patients at high risk of graft rejection [31, 32] .
In contrast to Peleg and colleagues who identified CMV disease as a risk factor for nocardiosis, CMV serostatus and CMV disease or infection were not significantly associated with We also identified older patient age and longer length of stay in the ICU after transplantation as risk factors for nocardiosis. Interestingly, we observed no significant difference when comparing the time between transplantation and the occurrence of nocardiosis between patients who had a short length of stay in the ICU after SOT (<8 days) and those with a long length of stay (≥8 days).
Therefore, these factors may reflect a general frailty of the recipient, making them more likely to develop complications after transplantation.
No intervention has yet been shown to prevent nocardiosis in transplant recipients.
Interestingly, administration of TMP-SMX (the most common treatment for nocardiosis) as prophylaxis against pneumocystosis was not found to effectively prevent nocardiosis in our study, or in the study by Peleg et al. [15] , although our study design does not allow definitive conclusions to be drawn regarding the use of TMP-SMX for this purpose. As described elsewhere, we have observed that occurrence of TMP-SMX-susceptible Nocardia infections was common in subjects receiving this agent as prophylaxis against pneumocystosis, suggesting that resistance to TMP-SMX was not responsible for the breakthrough nocardiosis [3, 14, 17] . A possible explanation for this lack of prophylactic effect is that the relatively low dose of TMP-SMX used to prevent pneumocystosis may be insufficient to prevent Nocardia infection. Indeed, HIV-infected patients, who usually receive a higher weekly dose of TMP-SMX, have a lower incidence of nocardiosis compared to SOT recipients [33] . Although the mean weekly dose of TMP-SMX was similar in cases and controls, it is difficult to interpret these data, because renal function, body weight and compliance also need to be taken into account.
No clinical, biological or radiological signs were specific for nocardiosis, but pulmonary nocardiosis (the most common presentation in our cohort) was associated with nodule(s) in 68/91 (74.7%) patients. Therefore, a nodular pneumonia occurring after SOT should raise suspicion of possible nocardiosis. Furthermore, our study demonstrated that CNS nocardiosis is common Once nocardiosis is suspected and confirmed in the microbiology laboratory, identification of Nocardia at the species level requires molecular tools, such as amplification and sequencing of the gene coding for the 16S rRNA or hsp65. Using such approaches, it has been shown that N. asteroides -the most frequently identified species until the end of the 1990s-is an uncommon cause of nocardiosis [19] . Because each species has its own antimicrobial susceptibility profile, accurate identification can help guide choice of empirical antibiotic therapy [1] . Previous studies of posttransplant nocardiosis rarely used sequencing as an identification tool, resulting in the frequent and incorrect identification of N. asteroides. In our study, partial sequencing was performed in 105/117 of our strains (89.7%). N. farcinica and N. nova complex were the two most frequently isolated species, identified in 35% (41/117) and 24% (28/117), respectively, of our European cases of nocardiosis after SOT. We identified no cases of N. asteroides.
Our retrospective study has several limitations. First, it was not possible to evaluate the role of potential risk factors that were not recorded in patients' medical records (e.g., environmental exposure to soil or decaying vegetation). Second, there were some missing data (Table 1) , so we were unable to analyze the role of biological variables in our multivariable analysis. However, conducting a prospective cohort study was considered impractical because of the rarity of post-SOT nocardiosis.
Interestingly, the all-cause mortality rate was 16.2% (19/117) in our cohort, a finding that is compatible with previous studies in which the mortality rate was about 20% [19] , suggesting that our cohort is representative of the population of solid organ transplant recipients with nocardiosis in western countries.
In conclusion, a high calcineurin inhibitor trough level in the month prior to diagnosis, use of tacrolimus at the time of diagnosis, corticosteroid dose at the time of diagnosis, patient age and 
